AstraZeneca and Bristol-Myers Squibb announce EU approval for diabetes drug Xigduo
The European Commission has granted marketing authorisation to AstraZeneca and Bristol-Myers Squibb's (BMS's) Xigduo (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) for the treatment of type 2 diabetes in the European …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Forxiga | Marketing | Metformin | Pharmaceuticals